BBB seminar
Juan Antonio Vizcaíno from the European Bioinformatics Institute, EMBL-EBI, Cambridge, UK, will give a talk entitled “Benefits of open science practices in proteomics and challenges arising from clinical datasets”.
Position: Proteomics Team Leader at the European Bioinformatics Institute
Research field: Proteomics, public repositories, open data, data standards
Main achievements: Vizcaíno’s team is responsible of the development of the PRIDE database (https://www.ebi.ac.uk/pride), the world-leading public repository for mass spectrometry proteomics data. Vizcaíno also co-founded and is coordinating the ProteomeXchange Consortium (http://www.proteomexchange.org), aiming to standardize data submission and dissemination in proteomics resources worldwide. Over the years, Vizcaíno has also heavily contributed to the development of open proteomics data standard formats, as part of the HUPO Proteomics Standards Initiative (PSI), and he is co-leading the ELIXIR Proteomics Community in Europe (https://elixir-europe.org/communities/proteomics).
Seminar focus: The recent increase in availability of proteomics data in the public domain has triggered numerous data re-use activities. I will highlight some of these ongoing efforts, including examples of machine learning approaches applied to public proteomics datasets. Proteomics is also increasingly used for clinical studies, resulting in potential ethical issues. I will describe the current state of the art, and the expected changes for the future in the context of data management practices in the field.
Thursday, November 3, 14:30
BBB seminar
Charalampos Tzoulis from the Department of Clinical Medicine, University of Bergen, will give a talk entitled «Mitochondria and Parkinson’s disease: from bench to bedside».
Seminar focus: Parkinson’s disease (PD) is a major cause of death and disability, with a rapidly growing global socioeconomic impact. Current treatments for PD make no substantial impact on disease progression and, despite several candidate neuroprotective therapies showing encouraging preclinical results, these have failed to show disease-modifying effects in clinical trials. A growing body of evidence suggests that therapies targeting mitochondria and NAD metabolism may confer neuroprotective effects in PD. This presentation will cover hallmark experimental evidence supporting these hypotheses, and illustrate how basic laboratory research led to the first clinical trial of NAD replenishment therapy in PD, which showed encouraging results (Cell Metabolism, Brakedal et al., doi: 10.1016/j.cmet.2022.02.001).
Neuromics research group: https://neuromics.org
Neuro-SysMed Center: https://neuro-sysmed.no
Chairperson: Aurora Martinez (aurora.martinez@uib.no), Dept. of Biomedicine
Thursday, November 10, 14:30